Abbott Laboratories (NYSE:ABT) shares fell about 4.8% after the company reported fourth-quarter results that met earnings ...

Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories forecast a 1Q profit that was lower than Wall Street expected and missed 4Q sales estimates after its ...

The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.